Danaher Bioprocessing Segment Returns to High-Single-Digit Growth, Boosts Fund Contribution
Danaher’s Bioprocessing segment returned to high-single-digit organic growth in Q4 2025, driving its inclusion among the Madison Large Cap Fund’s top five contributors. On February 23, shares closed at $210.92, with a one-month return of -10.53% and 12-month gain of 0.24%, supporting a $149.1 billion market cap.
1. Madison Fund Spotlight
Madison Investments’ Q4 2025 investor letter highlighted Danaher’s Bioprocessing segment returning to high-single-digit organic growth, naming it among the top five contributors alongside Alphabet and Parker-Hannifin. This improvement followed a period of slower Healthcare segment performance earlier in the year.
2. Stock Performance and Financials
Danaher shares closed at $210.92 on February 23, reflecting a one-month decline of 10.53% and a 0.24% gain over the past twelve months, with market capitalization at $149.099 billion. In 2025, the company reported $24.6 billion in sales and 2% core revenue growth across its Biotechnology, Life Sciences and Diagnostics segments.
3. Hedge Fund Interest
Danaher ranked 27th among the 30 most popular hedge fund stocks, with 124 portfolios holding the shares at the end of Q4 2025, up from 117 in the prior quarter. The increase signals growing institutional confidence in the company’s Bioprocessing recovery.